SANOMA CORPORATION: ACQUISITION OF OWN SHARES 12 November 2024

Sanoma Corporation, Stock exchange release, 12 November 2024 at 18:30 EET

SANOMA CORPORATION: ACQUISITION OF OWN SHARES 12 November 2024

Nasdaq Helsinki Ltd:

The company holds a total of 140,997 of its own shares (SANOMA) including the shares acquired on 12 November 2024.

Detailed information concerning the acquisition is attached to this stock exchange release.

On behalf of Sanoma Corporation


Skandinaviska Enskilda Banken AB (publ) Helsinki branch

Antti Salakka    Janne Tiihonen




Additional information

Kaisa Uurasmaa, Head of Investor Relations and Sustainability, tel. +358 40 560 5601

Sanoma

Sanoma is an innovative and agile learning and media company impacting the lives of millions every day. Our Sustainability Strategy is designed to maximise our positive ‘brainprint’ on society and to minimise our environmental footprint. We are committed to the UN Sustainable Development Goals and signatory to the UN Global Compact.

Our learning products and services enable teachers to develop the talents of every child to reach their full potential. We offer printed and digital learning content as well as digital learning and teaching platforms for primary, secondary and vocational education, and want to grow our business.

Our Finnish media provide independent journalism and engaging entertainment also for generations to come. Our unique cross-media position offers the widest reach and tailored marketing solutions for our business partners.

Today, we operate in twelve European countries and employ more than 5,000 professionals. In 2023, our net sales amounted to approx. 1.4bn€ and our operational EBIT margin excl. PPA was 12.6%. Sanoma shares are listed on Nasdaq Helsinki. More information is available at sanoma.com.

You May Also Be Interested In

• Erasca Announces Pricing of Upsized Public Offering of Common Stock
• ALZHEIMER'S BLOOD TEST COULD BRING HIGHLY ACCURATE DIAGNOSIS INTO EVERYDAY CLINICAL CARE
• Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain